Trial Profile

A Multicenter, Randomized, Double-Blind, Active-Controlled Trial of the Efficacy and Safety of Adding HSK7653 to Metformin in Chinese Patients With Type 2 Diabetes and Inadequate Glycaemic Control

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 20 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

23 Sep 2024 Results (n=465) evaluating the efficacy and safety of cofrogliptin compared with linagliptin (taken daily) in patients with type 2 diabetes inadequately controlled on metformin in China published in the Diabetes, Obesity and Metabolism.
06 Oct 2023 Results assessing the efficacy and safety of adding biweekly HSK7653 versus daily linagliptin in Chinese patients with type 2 diabetes and inadequate glycemic control on metformin monotherapy presented at the 59th Annual Meeting of the European Association for the Study of Diabetes
09 Dec 2022 Status changed from recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com